Avalanche Biotechnologies Obtains $55,000,000 Series B Funding Round

  • Feed Type
  • Date
    4/23/2014
  • Company Name
    Avalanche Biotechnologies
  • Mailing Address
    1555 Adams Drive Menlo Park, CA 94025 USA
  • Company Description
    Founded in 2006, Avalanche is a biotechnology company that develops technologies and products for sustained delivery of therapeutic proteins to the eye to treat wet age-related macular degeneration (AMD), as well as other ophthalmologic disorders, such as diabetic retinopathy, retinal degeneration, and glaucoma.
  • Website
    http://www.avalanchebiotech.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $55,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds from the Series B financing round will be used to advance the company’s clinical programs in retinal disorders, including Avalanche’s lead product, AVA-101, for wet AMD.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy